Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide

PHASE4CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

August 22, 2022

Study Completion Date

August 30, 2022

Conditions
Acute Mountain Sickness
Interventions
DRUG

Acetazolamide

Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.

DEVICE

Doctormate® (twice daily for 6 days)

Start RIPC training twice daily, 6 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the seventh day. At that time, the subject should have finished 13 times of RIPC training.

DEVICE

Doctormate® (forth daily for 3 days)

Start RIPC training forth daily, 3 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the forth day. At that time, the subject should have finished 13 times of RIPC training.

Trial Locations (1)

100053

Xuanwu Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Ji Xunming,MD,PhD

OTHER

NCT05023941 - Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide | Biotech Hunter | Biotech Hunter